{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:09:39Z","timestamp":1778904579129,"version":"3.51.4"},"reference-count":58,"publisher":"e-Century Publishing Corporation","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/kkqm4339","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:57:12Z","timestamp":1761728232000},"page":"7602-7611","source":"Crossref","is-referenced-by-count":2,"title":["Effects of drug administration routes on the efficacy and safety of treatments for systemic lupus erythematosus"],"prefix":"10.62347","volume":"17","author":[{"given":"Hong","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","unstructured":"Siegel CH and Sammaritano LR. Systemic lupus erythematosus: a review. JAMA 2024; 331: 1480-1491.","journal-title":"JAMA"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Ali A, Woods A, Porter C and Feldman SR. Tumid lupus erythematosus and systemic lupus erythematosus: a rare coexistence. BMJ Case Rep 2021; 14: e245196.","DOI":"10.1136\/bcr-2021-245196"},{"key":"ref2","unstructured":"Aronovitz Y, Oren D, Agbariah R, Vivante A and Tirosh I. Small fiber neuropathy as a presenting symptom of juvenile systemic lupus erythematosus. Isr Med Assoc J 2022; 24: 544-545."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Kassim FM, Wordefo DK, Berhanu M, Megersa SW and Tessema SA. Psychiatric manifestations of systemic lupus erythematosus: a brief review with two case-reports. SAGE Open Med Case Rep 2024; 12: 2050313X241229010.","DOI":"10.1177\/2050313X241229010"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.3390\/ijms24076578","article-title":"Advances in the pathogenesis and treatment of systemic lupus erythematosus","volume":"24","author":"Accapezzato","year":"2023","unstructured":"Accapezzato D, Caccavale R, Paroli MP, Gioia C, Nguyen BL, Spadea L and Paroli M. Advances in the pathogenesis and treatment of systemic lupus erythematosus. Int J Mol Sci 2023; 24: 6578.","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00296-023-05306-5","article-title":"Current treatment of systemic lupus erythematosus: a clinician’s perspective","volume":"43","author":"Katarzyna","year":"2023","unstructured":"Katarzyna PB, Wiktor S, Ewa D and Piotr L. Current treatment of systemic lupus erythematosus: a clinician’s perspective. Rheumatol Int 2023; 43: 1395-1407.","journal-title":"Rheumatol Int"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"101329","DOI":"10.1016\/j.rmcr.2020.101329","article-title":"Acute onset systemic lupus erythematosus interstitial lung disease: a case report","volume":"32","author":"Kobe","year":"2021","unstructured":"Kobe H, Arita M, Kadoba K, Niwa T, Tokioka F and Ishida T. Acute onset systemic lupus erythematosus interstitial lung disease: a case report. Respir Med Case Rep 2021; 32: 101329.","journal-title":"Respir Med Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/15269248231164175","article-title":"Perspectives on donor-derived cell-free DNA in kidney transplant recipients with systemic lupus erythematosus","volume":"33","author":"Williams","year":"2023","unstructured":"Williams MD, Gupta V, Chan EY and Olaitan O. Perspectives on donor-derived cell-free DNA in kidney transplant recipients with systemic lupus erythematosus. Prog Transplant 2023; 33: 182-183.","journal-title":"Prog Transplant"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","unstructured":"Aranow C, Allaart CF, Amoura Z, Bruce IN, Cagnoli PC, Chatham WW, Clark KL, Furie R, Groark J, Urowitz MB, van Vollenhoven R, Daniels M, Fox NL, Gregan YI, Henderson RB, van Maurik A, Ocran-Appiah JC, Oldham M, Roth DA, Shanahan D, Tak PP and Teng YO. Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. Ann Rheum Dis 2024; 83: 1502-1512.","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Kaneko S, Shimbo A, Irabu H, Yamamoto T and Shimizu M. Inverted-duplication-deletion of chromosome 10q identified in a patient with systemic lupus erythematosus. Pediatr Int 2023; 65: e15396.","DOI":"10.1111\/ped.15396"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Ying L, Hui W, Ming G, Yeping J and Fengmao Z. A rare case of cerebral aspergilloma in a pediatric patient with systemic lupus erythematosus. Pediatr Int 2023; 65: e15536.","DOI":"10.1111\/ped.15536"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"290","DOI":"10.11604\/pamj.2022.42.290.36118","article-title":"Case of a 30-year-female with systemic lupus erythematosus: a rare clinical image","volume":"42","author":"Jawade","year":"2022","unstructured":"Jawade S and Wankhede P. Case of a 30-year-female with systemic lupus erythematosus: a rare clinical image. Pan Afr Med J 2022; 42: 290.","journal-title":"Pan Afr Med J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.jaad.2023.01.020","article-title":"Differential effect of the 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus on different cutaneous lupus subtypes","volume":"88","author":"Shah","year":"2023","unstructured":"Shah S, Esaa FS, Baughman L, Gadarowski MB and Richardson CT. Differential effect of the 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus on different cutaneous lupus subtypes. J Am Acad Dermatol 2023; 88: 1370-1372.","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Tani C, Maffi M, Cascarano G, Signorini V, Zucchi D, Menchini M, Stagnaro C, Carli L, Elefante E, Ferro F, Cardelli C, Manca ML and Mosca M. When is the right time to change therapy? An observational study of the time to response to immunosuppressive drugs in systemic lupus erythematosus. Lupus Sci Med 2024; 11: e001207.","DOI":"10.1136\/lupus-2024-001207"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tibs.2024.01.012","article-title":"Glucocorticoid receptor signaling: intricacies and therapeutic opportunities","volume":"49","author":"Clarisse","year":"2024","unstructured":"Clarisse D, Van Moortel L, Van Leene C, Gevaert K and De Bosscher K. Glucocorticoid receptor signaling: intricacies and therapeutic opportunities. Trends Biochem Sci 2024; 49: 431-444.","journal-title":"Trends Biochem Sci"},{"key":"ref15","unstructured":"Polonini HC, Taylor S and Silva CCV. Compatibility of cetirizine hydrochloride, dutasteride, hydrocortisone acetate, nicotinamide, progesterone, and pyridoxine hydrochloride in trichosoltm, a natural vehicle for hair solutions. Int J Pharm Compd 2024; 28: 440-447."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jaad.2023.02.044","article-title":"Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus","volume":"89","author":"Chasset","year":"2023","unstructured":"Chasset F, Jaume L, Mathian A, Abisror N, Dutheil A, Barbaud A, Kottler D, Girard C, Jousse-Joulin S, Tauber M, Livideanu CB, Avettand-Fenoel V, Lhote R, Pha M and Amoura Z; EMSED (Etude des maladies systémiques en dermatologie) study group. Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus. J Am Acad Dermatol 2023; 89: 171-173.","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"13249","DOI":"10.1021\/acsnano.4c02420","article-title":"Dexamethasone-integrated mesenchymal stem cells for systemic lupus erythematosus treatment via multiple immunomodulatory mechanisms","volume":"18","author":"Ma","year":"2024","unstructured":"Ma W, Che J, Chen W, Wang D, Zhang H and Zhao Y. Dexamethasone-integrated mesenchymal stem cells for systemic lupus erythematosus treatment via multiple immunomodulatory mechanisms. ACS Nano 2024; 18: 13249-13265.","journal-title":"ACS Nano"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13256-022-03572-8","article-title":"Diagnosis of tuberculosis with autoimmune hepatitis-systemic lupus erythematosus overlap syndrome: a case report","volume":"16","author":"Shekhar","year":"2022","unstructured":"Shekhar, Gupta NY and Harisingani AR. Diagnosis of tuberculosis with autoimmune hepatitis-systemic lupus erythematosus overlap syndrome: a case report. J Med Case Rep 2022; 16: 428.","journal-title":"J Med Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"10049","DOI":"10.3390\/ijms221810049","article-title":"Glucocorticoid resistance: interference between the glucocorticoid receptor and the MAPK signalling pathways","volume":"22","author":"LM","year":"2021","unstructured":"Sevilla LM, Jiménez-Panizo A, Alegre-Martí A, Estébanez-Perpiñá E, Caelles C and Pérez P. Glucocorticoid resistance: interference between the glucocorticoid receptor and the MAPK signalling pathways. Int J Mol Sci 2021; 22: 10049.","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"110182","DOI":"10.1016\/j.clim.2024.110182","article-title":"Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus","volume":"262","author":"Mizui","year":"2024","unstructured":"Mizui M and Kono M. Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus. Clin Immunol 2024; 262: 110182.","journal-title":"Clin Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.55133\/eji.300415","article-title":"In vitro evaluation of the potential immunosuppressive effect of panobinostat on cultured lymphocytes retrieved from childhood systemic lupus erythematosus patients","volume":"30","author":"Yassin","year":"2023","unstructured":"Yassin NA, Abdelsalam M, El-Sabbagh AM, Morsy AI, Haleem AA, El-Shenbaby I, El Wakeel GA, Hammad A, Hamdy N, Abd-El Ghafaar DM, Elmarghany EB, Korkor MS and Eid R. In vitro evaluation of the potential immunosuppressive effect of panobinostat on cultured lymphocytes retrieved from childhood systemic lupus erythematosus patients. Egypt J Immunol 2023; 30: 145-154.","journal-title":"Egypt J Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13256-022-03478-5","article-title":"Systemic lupus erythematosus with trisomy X: a case report and review of the literature","volume":"16","author":"Luo","year":"2022","unstructured":"Luo F, Ye Q and Shen J. Systemic lupus erythematosus with trisomy X: a case report and review of the literature. J Med Case Rep 2022; 16: 281.","journal-title":"J Med Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1286649","DOI":"10.3389\/fmed.2023.1286649","article-title":"Myelodysplastic syndrome-like response after voriconazole treatment of systemic lupus erythematosus complicated with fungal infection: a case report","volume":"10","author":"Xie","year":"2023","unstructured":"Xie GL, Wang XS, Hu LY, Wang Y, Gu X and Xu YQ. Myelodysplastic syndrome-like response after voriconazole treatment of systemic lupus erythematosus complicated with fungal infection: a case report. Front Med (Lausanne) 2023; 10: 1286649.","journal-title":"Front Med (Lausanne)"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Hu Y, Yuan J, Wang B, Ma L and Zha Y. Efficacy of belimumab for severe childhood-onset systemic lupus erythematosus with diffuse proliferative glomerulonephritis: a case report. Medicine (Baltimore) 2023; 102: e34800.","DOI":"10.1097\/MD.0000000000034800"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"103129","DOI":"10.1016\/j.autneu.2023.103129","article-title":"Targeted stimulation of the vagus nerve reduces renal injury in female mice with systemic lupus erythematosus","volume":"250","author":"Shimoura","year":"2023","unstructured":"Shimoura CG, Stubbs CY, Chaudhari S, Dinh VQ and Mathis KW. Targeted stimulation of the vagus nerve reduces renal injury in female mice with systemic lupus erythematosus. Auton Neurosci 2023; 250: 103129.","journal-title":"Auton Neurosci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.1097\/MS9.0000000000002530","article-title":"Corticosteroid-induced bradycardia following high-dose methylprednisolone administration: a case report","volume":"86","author":"Zkib","year":"2024","unstructured":"Zkib J, Sattout R, Faour S, Haddad S, Bassut R, Swed W, Hritani S, Mansouer M and Ghabally M. Corticosteroid-induced bradycardia following high-dose methylprednisolone administration: a case report. Ann Med Surg (Lond) 2024; 86: 6300-6302.","journal-title":"Ann Med Surg (Lond)"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Arnaud L, Fabry-Vendrand C, Todea R, Vidal B, Cottin J, Bureau I, Bouée S and Thabut G. Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database. Lupus Sci Med 2025; 12: e001428.","DOI":"10.1136\/lupus-2024-001428"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"115301","DOI":"10.1016\/j.addr.2024.115301","article-title":"Towards more tolerable subcutaneous administration: review of contributing factors for improving combination product design","volume":"209","author":"Mathias","year":"2024","unstructured":"Mathias N, Huille S, Picci M, Mahoney RP, Pettis RJ, Case B, Helk B, Kang D, Shah R, Ma J, Bhattacharya D, Krishnamachari Y, Doucet D, Maksimovikj N, Babaee S, Garidel P, Esfandiary R and Gandhi R. Towards more tolerable subcutaneous administration: review of contributing factors for improving combination product design. Adv Drug Deliv Rev 2024; 209: 115301.","journal-title":"Adv Drug Deliv Rev"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Gupta AK, Talukder M, Keene SA and Bamimore MA. Is the safety of finasteride correlated with its route of administration: topical versus oral? A pharmacovigilance study with data from the united states food and drug administration adverse event reporting system. Int J Dermatol 2025; [Epub ahead of print].","DOI":"10.1111\/ijd.17957"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Narasimhalu N, Au K and Luisiri P. Case series: lingual infarction and autoamputation in systemic lupus erythematosus. J Clin Rheumatol 2021; 27: e42-e43.","DOI":"10.1097\/RHU.0000000000001386"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1457821","DOI":"10.3389\/fimmu.2024.1457821","article-title":"Tofacitinib for child-onset systemic lupus erythematosus","volume":"15","author":"Hou","year":"2024","unstructured":"Hou L, Zhou P, Zhao C, Wang X and Du Y. Tofacitinib for child-onset systemic lupus erythematosus. Front Immunol 2024; 15: 1457821.","journal-title":"Front Immunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"909","DOI":"10.12998\/wjcc.v11.i4.909","article-title":"Unusual presentation of systemic lupus erythematosus as hemophagocytic lymphohistiocytosis in a female patient: a case report","volume":"11","author":"Peng","year":"2023","unstructured":"Peng LY, Liu JB, Zuo HJ and Shen GF. Unusual presentation of systemic lupus erythematosus as hemophagocytic lymphohistiocytosis in a female patient: a case report. World J Clin Cases 2023; 11: 909-917.","journal-title":"World J Clin Cases"},{"key":"ref33","unstructured":"Aparisi Gómez MP, Wáng YJ, Yu JS, Johnson R and Chang CY. Dual-energy X-ray absorptiometry for osteoporosis screening: AJR expert panel narrative review. AJR Am J Roentgenol 2025; [Epub ahead of print]."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1422062","DOI":"10.3389\/fphar.2024.1422062","article-title":"Efficacy of combination therapy of vitamin D and bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis","volume":"15","author":"Yang","year":"2024","unstructured":"Yang Y, Yang M, Su X and Xie F. Efficacy of combination therapy of vitamin D and bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis. Front Pharmacol 2024; 15: 1422062.","journal-title":"Front Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4037\/aacnacc2023222","article-title":"Modifying type of insulin to manage steroid-induced hyperglycemia: a case report","volume":"34","author":"Pollock","year":"2023","unstructured":"Pollock FM. Modifying type of insulin to manage steroid-induced hyperglycemia: a case report. AACN Adv Crit Care 2023; 34: 39-46.","journal-title":"AACN Adv Crit Care"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Zhang SX, Wang J, Chen JW, Zhang MX, Zhang YF, Hu FY, Lv ZQ, Gao C, Li YF and Li XF. The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus. Ann Rheum Dis 2021; 80: e177.","DOI":"10.1136\/annrheumdis-2019-216504"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/molecules29040747","article-title":"Neuropsychiatric systemic lupus erythematosus: molecules involved in its imunopathogenesis, clinical features, and treatment","volume":"29","author":"Justiz-Vaillant","year":"2024","unstructured":"Justiz-Vaillant AA, Gopaul D, Soodeen S, Arozarena-Fundora R, Barbosa OA, Unakal C, Thompson R, Pandit B, Umakanthan S and Akpaka PE. Neuropsychiatric systemic lupus erythematosus: molecules involved in its imunopathogenesis, clinical features, and treatment. Molecules 2024; 29: 747.","journal-title":"Molecules"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s42358-024-00366-y","article-title":"Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study","volume":"64","author":"Luca Montes RA","year":"2024","unstructured":"de Luca Montes RA, Huq M, Godfrey T, Oon S, Calderone A, Kandane-Rathnayake R, Louthrenoo W, Luo SF, Jan Wu YJ, Golder V, Lateef A, Navarra SV, Zamora L, Hamijoyo L, Sockalingam S, An Y, Li Z, Katsumata Y, Harigai M, Chan M, Goldblatt F, O’Neill S, Lau CS, Cho J, Hoi A, Karyekar CS, Morand EF and Nikpour M. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study. Adv Rheumatol 2024; 64: 38.","journal-title":"Adv Rheumatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/ibd\/izab254","article-title":"Characterization of mycophenolate mofetil gastrointestinal toxicity and risk factors for severe disease and poor prognosis","volume":"28","author":"Bhattacharya","year":"2022","unstructured":"Bhattacharya S, Stoleru G, Patel P, Abutaleb A, Stashek K and Cross RK. Characterization of mycophenolate mofetil gastrointestinal toxicity and risk factors for severe disease and poor prognosis. Inflamm Bowel Dis 2022; 28: 811-814.","journal-title":"Inflamm Bowel Dis"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Chow KW, Sweis JJG, Alawneh D, Jetanalin P, Ascoli C, Kuschel S, Hoyer S, Braniecki M and Sweiss N. Bullous systemic lupus erythematosus successfully treated with intravenous immunoglobulin and mycophenolate mofetil. Cureus 2023; 15: e45800.","DOI":"10.7759\/cureus.45800"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.4103\/ijo.IJO_299_22","article-title":"Bilateral secondary angle-closure glaucoma and ciliochoroidal effusion as an initial manifestation of systemic lupus erythematosus","volume":"70","author":"Senthilkumar","year":"2022","unstructured":"Senthilkumar VA, Vineela P, Mishra C and Ramesh S. Bilateral secondary angle-closure glaucoma and ciliochoroidal effusion as an initial manifestation of systemic lupus erythematosus. Indian J Ophthalmol 2022; 70: 2659-2661.","journal-title":"Indian J Ophthalmol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/mr\/roac156","article-title":"Subcutaneous injection of methotrexate: advantages in the treatment of rheumatoid arthritis","volume":"33","author":"Tanaka","year":"2023","unstructured":"Tanaka Y. Subcutaneous injection of methotrexate: advantages in the treatment of rheumatoid arthritis. Mod Rheumatol 2023; 33: 633-639.","journal-title":"Mod Rheumatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s41927-024-00439-x","article-title":"Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients","volume":"8","author":"Sun","year":"2024","unstructured":"Sun S, Zhang X, Guo Q, Tang X, Shen W, Liang J, Yao G, Geng L, Ding S, Chen H, Wang H, Hua B, Zhang H, Feng X, Jin Z and Sun L. Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients. BMC Rheumatol 2024; 8: 68.","journal-title":"BMC Rheumatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"7984","DOI":"10.1038\/s41598-021-87095-0","article-title":"Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis","volume":"11","author":"Miao","year":"2021","unstructured":"Miao Q, Yan L, Zhou Y, Li Y, Zou Y, Wang L, Bai Y and Zhang J. Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis. Sci Rep 2021; 11: 7984.","journal-title":"Sci Rep"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000527223","article-title":"Comparative efficacy and safety of biological agents in the treatment of lupus nephritis: a network meta-analysis","volume":"108","author":"Lee","year":"2023","unstructured":"Lee YH and Song GG. Comparative efficacy and safety of biological agents in the treatment of lupus nephritis: a network meta-analysis. Pharmacology 2023; 108: 17-26.","journal-title":"Pharmacology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"284","DOI":"10.5414\/CP204406","article-title":"A crossover study to evaluate the pharmacokinetics and bioequivalence of hydroxychloroquine tablets in healthy Chinese subjects","volume":"62","author":"Feng","year":"2024","unstructured":"Feng J, Kuang SY, Wan JH, Li R, Zhu YJ, Cai BL, Guan L and Zhang Z. A crossover study to evaluate the pharmacokinetics and bioequivalence of hydroxychloroquine tablets in healthy Chinese subjects. Int J Clin Pharmacol Ther 2024; 62: 284-292.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Sbidian E, Penso L, Herlemont P, Botton J, Baricault B, Semenzato L, Drouin J, Weill A, Dray-Spira R and Zureik M. Comment on ‘Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19’ by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France. Ann Rheum Dis 2023; 82: e117.","DOI":"10.1136\/annrheumdis-2020-218647"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1383343","DOI":"10.3389\/fimmu.2024.1383343","article-title":"Hydroxychloroquine-induced hyperpigmentation of the skin and bull’s-eye maculopathy in rheumatic patients: a case report and literature review","volume":"15","author":"Peng","year":"2024","unstructured":"Peng JP, Yang XY, Luo F, Yuan XM, Xiong H, Ma WK and Yao XM. Hydroxychloroquine-induced hyperpigmentation of the skin and bull’s-eye maculopathy in rheumatic patients: a case report and literature review. Front Immunol 2024; 15: 1383343.","journal-title":"Front Immunol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1196783","DOI":"10.3389\/fphar.2023.1196783","article-title":"Hydroxychloroquine-induced retinal toxicity","volume":"14","author":"IH","year":"2023","unstructured":"Yusuf IH, Charbel Issa P and Ahn SJ. Hydroxychloroquine-induced retinal toxicity. Front Pharmacol 2023; 14: 1196783.","journal-title":"Front Pharmacol"},{"key":"ref50","unstructured":"Kane M. Hydroxychloroquine Therapy and G6PD Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2023."},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Forouzan P and Cohen PR. Systemic lupus erythematosus presenting as alopecia areata. Cureus 2020; 12: e8724.","DOI":"10.7759\/cureus.8724"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/ard-2022-222672","article-title":"Livedo racemosa and thrombotic vasculitides of scalp in systemic lupus erythematosus","volume":"81","author":"JY","year":"2022","unstructured":"Lee JY, Tsai CY and Liao HT. Livedo racemosa and thrombotic vasculitides of scalp in systemic lupus erythematosus. Ann Rheum Dis 2022; 81: 1474.","journal-title":"Ann Rheum Dis"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.abd.2022.09.005","article-title":"Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects","volume":"98","author":"ECSd","year":"2023","unstructured":"Vale ECSd and Garcia LC. Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects. An Bras Dermatol 2023; 98: 355-372.","journal-title":"An Bras Dermatol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ad.2020.04.021","article-title":"RF-2019 classification criteria for systemic lupus erythematosus","volume":"113","author":"Serra-Garcia","year":"2022","unstructured":"Serra-Garcia L, Barba PJ and Morgado-Carrasco D. RF-2019 classification criteria for systemic lupus erythematosus. Actas Dermosifiliogr 2022; 113: 310-312.","journal-title":"Actas Dermosifiliogr"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/00498254.2023.2223666","article-title":"Meeting report: DMDG peptide and oligonucleotide ADME workshop 2022","volume":"53","author":"Christensen","year":"2023","unstructured":"Christensen JK, Bjornsdottir I, Sonesson A and Hood S. Meeting report: DMDG peptide and oligonucleotide ADME workshop 2022. Xenobiotica 2023; 53: 332-337.","journal-title":"Xenobiotica"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1177\/24725552211017520","article-title":"Validating ADME QSAR models using marketed drugs","volume":"26","author":"Siramshetty","year":"2021","unstructured":"Siramshetty V, Williams J, Nguyễn ÐT, Neyra J, Southall N, Mathé E, Xu X and Shah P. Validating ADME QSAR models using marketed drugs. SLAS Discov 2021; 26: 1326-1336.","journal-title":"SLAS Discov"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.3390\/pharmaceutics15112619","article-title":"The trends and future prospective of in silico models from the viewpoint of adme evaluation in drug discovery","volume":"15","author":"Komura","year":"2023","unstructured":"Komura H, Watanabe R and Mizuguchi K. The trends and future prospective of in silico models from the viewpoint of adme evaluation in drug discovery. Pharmaceutics 2023; 15: 2619.","journal-title":"Pharmaceutics"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0166598.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:44:53Z","timestamp":1769064293000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0166598.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/kkqm4339","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}